skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Issue

A product was about to go generic within the metastatic renal cell carcinoma (mRCC) indication. Our client wished to understand the potential impact of the competitor’s drug going generic on their brand and whether there would be any spill-over effects

 

Approach

Pharma Intelligence Consulting selected a set of historical analog drugs to model past benchmarking.

 We adopted five analytical methods to selecting the right analogs:

1) Bivariate analysis 2) Time series progression 3) Unit price differential 4) Market share evolution and 5) Weighted mean prioritization

 

Outcomes

 

Our comprehensive market report identified the most appropriate analogs for this therapeutic area and helped the client quantify the relationship between price-volume, and better understand the impact that pricing strategies can have on demand post LOE. Our analysis further outlined the speed and extent to which generic penetration occurs and the spill- over effects on share across the category. 

Our market segmentation based on the risk of generic exposure enabled the client to effectively strategize across regions.

Next steps

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now